The combination of cagrilintide 2.4 mg and semaglutide 2.4 mg was superior to semaglutide alone for weight loss and HbA1c ...

Novo Nordisk NVO announced positive top-line data from a late-stage study in its global REIMAGINE clinical study program for ...

Taking oral semaglutide may reduce heart-related hospitalizations and deaths among those with a history of heart failure and ...

Feb 2 (Reuters) - Novo Nordisk said on Monday its experimental next-generation weight-loss drug CagriSema showed greater ...

In October 2025, Skye reported top-line 26-week data from CBeyond showing that the nimacimab and semaglutide combination cohort achieved clinically meaningful weight loss compared with semaglutide ...

Once-weekly CagriSema significantly reduced HbA1c and body weight vs semaglutide in patients with type 2 diabetes in the REIMAGINE 2 trial.

Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema ...

Topline results from the REIMAGINE 2 trial involving 2,728 adults with type 2 diabetes inadequately controlled on metformin ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Nausea is the most common side effect of semaglutide, the ...

In the latest bunch of recommendations from the European Medicines | Sanofi, Novo Nordisk, UCB and others received positive ...

A large meta-analysis, published in Diabetology & Metabolic Syndrome, suggested that semaglutide improved several liver-related and metabolic outcomes in people with or at risk of developing MASH, ...

Danish drugmaker Novo Nordisk has announced headline results from REIMAGINE 2, a Phase III study from the global REIMAGINE clinical trial program.